We are live on
!
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$936M
1-Year Est. Return
195%
This Fund
S&P 500
This Quarter
Est. Return
+7.14%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$3.92B
AUM Growth
+$223M
(+6%)
Cap. Flow
+$233M
Cap. Flow
% of AUM
5.95%
Top 10 Holdings %
Top 10 Hldgs %
36.15%
Holding
133
New
20
Increased
42
Reduced
20
Closed
29
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$94.6M |
| 2 |
AstraZeneca
AZN
|
+$82.2M |
| 3 |
Baxter International
BAX
|
+$68.1M |
| 4 |
Caribou Biosciences
CRBU
|
+$60.5M |
| 5 |
Stevanato
STVN
|
+$59.9M |
Top Sells
| 1 |
Maravai LifeSciences
MRVI
|
+$124M |
| 2 |
Medtronic
MDT
|
+$66.4M |
| 3 |
Biogen
BIIB
|
+$63.7M |
| 4 |
NeoGenomics
NEO
|
+$61.7M |
| 5 |
Eli Lilly
LLY
|
+$58.1M |
Sector Composition
| 1 | Healthcare | 97.34% |
| 2 | Technology | 1.13% |
| 3 | Financials | 0.61% |
| 4 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.6B
| $380M | 9.68% |
+3,021,000
| New | +$389M |
|
|
XLRN
2
CALL
DELISTED
Acceleron Pharma
XLRN
| $211M | 5.39% |
+1,228,100
| New | +$161M |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $188M | 4.79% |
1,062,400
+309,400
| +41% | +$49.8M |
|
4
Arvinas
ARVN
$534M
| $184M | 4.68% |
2,234,700
+380,700
| +21% | +$33.6M |
|
5
AbbVie
ABBV
$431B
| $174M | 4.44% |
1,613,200
+128,800
| +9% | +$14.7M |
|
6
Vertex Pharmaceuticals
VRTX
$121B
| $168M | 4.28% |
926,400
-23,600
| -2% | -$4.61M |
|
7
Zentalis Pharmaceuticals
ZNTL
$340M
| $166M | 4.24% |
2,493,800
+333,800
| +15% | +$19.3M |
|
8
Avantor
AVTR
$7.65B
| $133M | 3.39% |
3,247,700
+67,700
| +2% | +$2.65M |
|
|
BHVN
9
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $130M | 3.31% |
934,200
+51,700
| +6% | +$6.46M |
|
10
Syndax Pharmaceuticals
SNDX
$2.08B
| $92.2M | 2.35% |
4,823,400
+208,400
| +5% | +$3.47M |
|
|
11
Regeneron Pharmaceuticals
REGN
$69.7B
| $92.2M | 2.35% |
+152,300
| New | +$94.6M |
|
|
SGEN
12
DELISTED
Seagen Inc. Common Stock
SGEN
| $91.2M | 2.32% |
537,000
-103,000
| -16% | -$16M |
|
|
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $90.5M | 2.31% |
826,000
+258,000
| +45% | +$26.8M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $85.5M | 2.18% |
832,000
+268,800
| +48% | +$25M |
|
|
15
AstraZeneca
AZN
$261B
| $84.8M | 2.16% |
+706,000
| New | +$82.2M |
|
16
Neurocrine Biosciences
NBIX
$17.3B
| $81.4M | 2.08% |
848,900
+167,900
| +25% | +$15.9M |
|
17
Alnylam Pharmaceuticals
ALNY
$37.3B
| $80.6M | 2.06% |
427,000
+232,000
| +119% | +$43.5M |
|
|
18
Eli Lilly
LLY
$1.03T
| $76.2M | 1.94% |
330,000
-235,500
| -42% | -$58.1M |
|
19
Nuvation Bio
NUVB
$2.05B
| $72.2M | 1.84% |
7,263,488
+297,112
| +4% | +$2.69M |
|
20
Natera
NTRA
$39.7B
| $71.2M | 1.81% |
638,700
+202,700
| +46% | +$23.2M |
|
|
HOLX
21
DELISTED
Hologic
HOLX
| $69.8M | 1.78% |
945,400
-263,400
| -22% | -$19.8M |
|
|
22
Baxter International
BAX
$11.4B
| $69.3M | 1.77% |
+862,000
| New | +$68.1M |
|
|
ARNA
23
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $67.8M | 1.73% |
1,139,000
+196,000
| +21% | +$11.6M |
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $66.6M | 1.7% |
4,100,000
+2,699,990
| +193% | +$29.4M |
|
25
United Therapeutics
UTHR
$22.6B
| $64.8M | 1.65% |
351,000
+114,600
| +48% | +$22.6M |
|
Similar funds
NM
LM
IF
PWAM
CM
LJAC
PO
SH